Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1 by Caroline Robert (15032672)

Subjects:

Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1 by Caroline Robert (15032672)

Subjects:

Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1 by Caroline Robert (15032672)

Subjects:

Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1 by Caroline Robert (15032672)

Subjects:

Supplementary file 1_Single-cell transcriptomics identifies FOSL1-regulated IGFBP3+ melanoma subtype as a neuro-immunoregulatory signaling hub facilitating tumor progression.docx by Wenjia Ge (22687361)

Subjects:

Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma by Jitske van den Bulk (17142147)

Subjects:

Supplementary Table S4 from Neoantigen Targetability in Progressive Advanced Melanoma by Jitske van den Bulk (17142147)

Subjects:

Supplementary Table S1 from Neoantigen Targetability in Progressive Advanced Melanoma by Jitske van den Bulk (17142147)

Subjects:

Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma by Jitske van den Bulk (17142147)

Subjects:

Supplementary Table S3 from Neoantigen Targetability in Progressive Advanced Melanoma by Jitske van den Bulk (17142147)

Subjects:

Supplementary Table 2 from Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis by Nneoma Adaku (16991063)

Subjects:

Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors by Joseph Toker (15399882)

Subjects:

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors by Joseph Toker (15399882)

Subjects:

Supplementary Table 3 from Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis by Nneoma Adaku (16991063)

Subjects:

Supplementary Data 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma by Alexander N. Shoushtari (15023909)

Subjects:

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors by Joseph Toker (15399882)

Subjects:

Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors by Joseph Toker (15399882)

Subjects:

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors by Joseph Toker (15399882)

Subjects:

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors by Joseph Toker (15399882)

Subjects:

Supplementary Table 1 from Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis by Nneoma Adaku (16991063)

Subjects: